PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

MHRA approves label extension for Vertex’s Kaftrio combo

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a label extension for Vertex’s cystic fibrosis (CF) treatment Kaftrio in combination with ivacaftor.
Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor is now available in Great Britain for the treatment of CF in all patients aged 12 years and older, who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
In April, the European Commission (EC) also approved this label extension for Vertex’s triple combination CF treatment.
This allowed eligible patients in the Republic of Ireland, Northern Ireland, Denmark and Luxembourg to gain access to the expanded indication for Kaftrio thank to long-term reimbursement agreements.
The label extension approval was supported by results of three Phase III studies in people aged 12 years and older with CF, which evaluated the treatment regimen in patients with a range of mutations.
Vertex utilized the EC decision reliance procedure in Great Britain – following this MHRA approval, the long-term reimbursement agreements that Vertex has in place in England, Scotland and Wales means that the patients who are now eligible for Kaftrio will get access ‘shortly’.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026